Business eyes up development of new glaucoma treatment

Article

Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. The unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets.

Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. The unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets.

One of the reasons these large entities are so interested in this project is because of a recent article in the Review of Ophthalmology which supports the development of a new class of glaucoma drugs now being tested by Canadian Bio Med Systems, Inc. (CBMS). The article entitled Glaucoma Drugs: The Search for New Options, quotes David Epstein, MD, Chairman of Ophthalmology at Duke University School of Medicine. Dr Epstein points out that the approach of improving aqueous outflow in the eye is: "The most logical approach to treating glaucoma."

The new compound being developed by CBMS in conjunction with Ocular Therapeutics, specifically targets a portion of the eye, Schlemm's Canal, which is critical in achieving aqueous outflow and lowering intraocular pressure. This novel approach to treatment may require application of the drug every three months, or even less often, rather that twice per day. It could revolutionize the treatment for glaucoma.

Dr Epstein points out the commercial aspects of such a potential drug that improves aqueous outflow by saying that when such a drug is developed "you will see every major pharmaceutical company jump on the bandwagon and want to have an outflow drug" he says, "Then in retrospect, every one will say 'Why didn't we work on this drug sooner."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.